<DOC>
	<DOC>NCT02675452</DOC>
	<brief_summary>At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma</brief_summary>
	<brief_title>AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.</brief_title>
	<detailed_description>This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma. The study will be conducted in three parts.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>INCLUSION CRITERIA: Pathologically documented, multiple myeloma relapsed or refractory disease after at least 2 lines of therapy, Must be willing and able to undergo bone marrow biopsy at screening, Measurable disease per the IMWG response criteria, Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 2, Satisfactory hematological function without transfusion or growth factor support, Subjects should not have received platelet transfusions for at least 1 week prior to screening, Hemoglobin &gt; 8 g/dL, Subjects may receive RBC transfusions or receive supportive care), Other Inclusion Criteria May Apply. EXCLUSION CRITERIA: Previously received an allogeneic stem cell transplant within 6 months OR having received immunosuppressive therapy within the last three months OR having signs or symptoms of acute or chronic graftversushost disease, Autologous stem cell transplant less than 90 days prior to study day 1, Multiple myeloma with IgM subtype, POEMS syndrome, Existing plasma cell leukemia, Waldenstrom's macroglobulinemia, Amyloidosis, Glucocorticoid therapy (prednisone &gt; 30 mg/day or equivalent) within 7 days prior to starting treatment, Topical or inhaled corticosteroids are permitted, Infection requiring intravenous antiinfective treatments within 1 week of study enrollment (day 1), Other exclusion Criteria May Apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>